Cantor Fitzgerald restated their buy rating on shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a research note issued to investors on Tuesday morning.

VRX has been the subject of a number of other research reports. J P Morgan Chase & Co set a $10.00 target price on Valeant Pharmaceuticals International and gave the stock a hold rating in a report on Monday, July 17th. BTIG Research reiterated a neutral rating on shares of Valeant Pharmaceuticals International in a report on Wednesday, May 10th. BMO Capital Markets reiterated a market perform rating on shares of Valeant Pharmaceuticals International in a report on Wednesday, May 10th. Guggenheim assumed coverage on Valeant Pharmaceuticals International in a report on Saturday, June 17th. They set a buy rating and a $18.00 target price for the company. Finally, Wells Fargo & Company reiterated an underperform rating and set a $9.00 target price on shares of Valeant Pharmaceuticals International in a report on Thursday, August 10th. Five equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have issued a buy rating to the company. The company currently has an average rating of Hold and an average price target of $17.67.

Shares of Valeant Pharmaceuticals International (VRX) opened at 13.24 on Tuesday. Valeant Pharmaceuticals International has a 12-month low of $8.31 and a 12-month high of $31.84. The company’s market cap is $4.61 billion. The stock has a 50 day moving average of $15.84 and a 200 day moving average of $13.40.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The business had revenue of $2.23 billion during the quarter, compared to analysts’ expectations of $2.23 billion. During the same quarter in the previous year, the business earned ($0.88) EPS. The company’s revenue for the quarter was down 7.7% on a year-over-year basis. Equities research analysts predict that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current fiscal year.

WARNING: This piece was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://theolympiareport.com/2017/08/30/valeant-pharmaceuticals-international-inc-vrx-given-buy-rating-at-cantor-fitzgerald.html.

In other news, Director Schutter Richard U. De purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The shares were acquired at an average cost of $14.33 per share, with a total value of $143,300.00. Following the transaction, the director now owns 77,479 shares in the company, valued at approximately $1,110,274.07. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 5.87% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. ValueAct Holdings L.P. increased its position in shares of Valeant Pharmaceuticals International by 20.0% in the first quarter. ValueAct Holdings L.P. now owns 17,997,224 shares of the specialty pharmaceutical company’s stock worth $198,509,000 after buying an additional 3,002,963 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Valeant Pharmaceuticals International by 4.2% in the second quarter. Vanguard Group Inc. now owns 7,274,717 shares of the specialty pharmaceutical company’s stock worth $125,853,000 after buying an additional 294,643 shares during the last quarter. Bank of Montreal Can increased its position in shares of Valeant Pharmaceuticals International by 9.8% in the second quarter. Bank of Montreal Can now owns 6,330,670 shares of the specialty pharmaceutical company’s stock worth $109,521,000 after buying an additional 564,215 shares during the last quarter. OppenheimerFunds Inc. increased its position in shares of Valeant Pharmaceuticals International by 17.1% in the first quarter. OppenheimerFunds Inc. now owns 4,489,169 shares of the specialty pharmaceutical company’s stock worth $49,516,000 after buying an additional 656,116 shares during the last quarter. Finally, CIBC World Markets Inc. increased its position in shares of Valeant Pharmaceuticals International by 2.3% in the second quarter. CIBC World Markets Inc. now owns 3,741,413 shares of the specialty pharmaceutical company’s stock worth $64,726,000 after buying an additional 83,592 shares during the last quarter. Hedge funds and other institutional investors own 50.49% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.